- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2026 Financial Results | 914 | PR Newswire | SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing... ► Artikel lesen | |
| 06.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Sera Prognostics outlines plan to expand partner programs to 15-17 states by year-end 2026 while maintaining cash runway through 2028 | 1 | Seeking Alpha | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 18.03. | Sera Prognostics: Aktie fällt trotz Gewinnüberraschung nach schwachen Umsatzzahlen | 2 | Investing.com Deutsch | ||
| 18.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter And Full Year 2025 Financial Results | 291 | PR Newswire | SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 18.03. | Sera Prognostics: EPS übertrifft Schätzungen um 0,03 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 18.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | Sera Prognostics: Positive Studiendaten zu Frühgeburtentest beflügeln Aktie | 1 | Investing.com Deutsch | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 15.12.25 | Jefferies initiates Sera Prognostics stock with Buy rating on preterm birth test | 1 | Investing.com | ||
| 15.12.25 | Jefferies stuft Sera Prognostics mit "Buy" ein - Frühgeburtentest als Kurstreiber | 3 | Investing.com Deutsch | ||
| 13.11.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2025 Financial Results | 839 | PR Newswire | SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 01.10.25 | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 215 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 06.08.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 164 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,525 | -1,93 % | NanoRepro: Mit Elan gestartet | "Wir sind auf einem guten Weg", sagt Lisa Jüngst, CEO von NanoRepro, am Ende ihrer Präsentation auf der Frühjahrskonferenz in Frankfurt. Die Aufgabenstellung könnte dabei ambitionierter kaum sein. Immerhin... ► Artikel lesen | |
| OCUGEN | 1,182 | -1,66 % | Ocugen schließt Platzierung von Wandelanleihen über 130 Millionen US-Dollar ab | ||
| VIKING THERAPEUTICS | 26,400 | +1,15 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,430 | +1,42 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| BIOCRYST PHARMACEUTICALS | 7,912 | +1,88 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release | ||
| IBIO | 1,274 | +0,39 % | iBio, Inc. - 10-Q, Quarterly Report | ||
| ARBUTUS BIOPHARMA | 3,610 | -1,10 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,020 | -0,97 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | 2025 was a year of tenacity, strategic transactions and building traction for RedHill
Talicia® business transformed:
Formation of Talicia Holdings Inc. (THI) and... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,457 | +1,67 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| MANNKIND | 2,810 | +5,48 % | MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program... ► Artikel lesen | |
| ALDEYRA | 1,410 | -2,76 % | Aldeyra Therapeutics: Aufsichtsratsmitglied Martin J. Joyce tritt nicht zur Wiederwahl an | ||
| TRAWS PHARMA | 1,950 | +3,72 % | Traws Pharma, Inc.: Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results | Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,438 | +6,13 % | Coherus Oncology, Inc.: Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $11.8 million in Q1 2026 - - Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections... ► Artikel lesen |
SERA PROGNOSTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,58 % bei einem Aktienkurs von 1,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.